Press

EU-AIMS Kick-off

EU-AIMS was kicked off with a Kick-off Meeting which took place at Zurich from 3 - 4 April 2012 as one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for autism spectrum disorder (ASD).

The photo shows from left to right: Prof. Dr. Declan Murphy (Managing Director of EU-AIMS, Head of Department of Forensic and Neurodevelopmental Sciences (IOP), King's College London), Prof. Dr. Anirvan Ghosh (Head of Discovery for Central Nervous System (CNS) at F. Hoffmann – La Roche), Prof. Dr. Michel Goldman (Executive Director of IMI - Innovative Medicine Initiative), and Dr. Will Spooren (Coordinator of EU-AIMS, Head Neurodevelopmental and Behavioral Neuroscience at F. Hoffmann – La Roche).

This meeting was restricted only for EU-AIMS members.
Read the EU-AIMS Kick-Off press release!

EU-AIMS Kick-Off press release (270 KB)

Next Annual Meeting

The next Annual Meeting of EU-AIMS will take place April 24-25^th 2014, at the Lilly Research Centre in Windlesham, UK. This meeting will be hosted by Eli Lilly.

News

13.05.2013

EU-AIMS - A Multicentre Study fro Developing New Medications

May 13th, a stakeholder forum was organized for all CNS reletated IMI projects in Brussels. EU-AIMS was also presented and the project was highly rated. Please follow the link and you will get an update on our first year results!

EU-AIMS presentation Stakeholder forum May 13th, 2013

23.08.2012

IMI autism project EU-AIMS on the cover of Nature

deCODE is whole genome sequencing a large number of individuals with autism and their parents. The results of this effort will provide us with an overview of the, de novo and segregating, mutations contributing to the risk of autism.

Rate of de novo mutations and the importance of father's age to disease risk? by Kong et al. Nature

Consortium

Quicklinks

Workpackages

Home